Quantcast

Needle-Free Delivery: Technology and Market Forecast 2014-2024 - WCAX.COM Local Vermont News, Weather and Sports-

Needle-Free Delivery: Technology and Market Forecast 2014-2024

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, Aug. 28, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Needle-Free Delivery: Technology and Market Forecast 2014-2024

http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html

Report Details

Needle-free delivery – discover technological and commercial prospects
What does the future hold for the needle-free delivery market? Visiongain's brand new report shows you the potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 187 page report provides 103 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions.
Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT), company profiles and commercial developments. Read the full transcript of five exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
- Robert E. Sievers, CEO and President, Aktiv-Dry LLC
- David Hoey, CEO, Vaxxas
- Professor Mark Kendall, Inventor of the Nanopatch and Co-Founder of Vaxxas
- John Turanin, Vice President and General Manager, Zogenix Technologies
- Mark Logomasini, President and CEO, Bioject Medical Technologies

You will find prospects for key submarkets

In addition to analyses of the overall world market, you will see revenue forecasting of two world-level submarkets to 2024:
• Jet injectors market
• Competing needle-free technology market

The competing needle-free technology market is further segmented into:
• Novel needle technology (includes microneedles and pen needles)
• Inhaler technology
• Patch technology

Our investigation shows business research and analysis with individual revenue forecasts and discussions. How will those needle-free technologies expand? Which applications will generate most money? This study will allow you to thoroughly understand the industry, finding the most promising places for investments and sales.

What are the prospects in the leading regions and countries?

Events and progress worldwide will influence the market. In our study you will find individual revenue forecasts to 2024 for 10 national markets:
• US
Japan
Germany
France
• UK
Italy
Spain
• Rest of Europe
China
India
• Row

Many opportunities exist within the needle-free delivery market. Greater uptake of existing technology and products worldwide will also stimulate the industry and market. With our new investigation you will gain business research and analysis with individual sales predictions and discussions. You will find analysis of competition, as well as commercial drivers and restraints. See what is likely to achieve the most success.

Leading companies and potential for market growth

Overall world revenue for the needle-free delivery market will reach $1.2bn in 2014, our work forecasts. We predict strong revenue growth from 2014 to 2024. Our work shows you what organisations hold greatest potential.

See profiles of 10 leading companies, including these:
• Antares Pharma
• Zogenix
• Bioject Medical Technologies
• 3M
• Medical International Technology (MIT)
• D'Antonio Consultants International (DCI)
• PharmaJet
• Akra Dermojet
• Injex Pharma
• Glide Pharma

In general, a company profile gives you the following information:
• Overview of the company, including its history in the market
• Discussion of a company's activities and outlook including descriptions of leading products
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, inc. alliances, partnerships and joint ventures

What issues will affect the needle-free delivery market?

Our new report discusses issues and events affecting the needle-free delivery market. You will find discussions, including qualitative analyses:
• Developments in transdermal delivery
• Growing demand for minimally invasive delivery methods
• Mass immunisation programmes across the globe
• Booming global vaccine market
• Shift towards home administration settings
• Increasing regulatory scrutiny
• Inefficient manufacturing processes leading to costly needle-free technologies

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Needle-Free Delivery: Technology and Market Forecast 2014-2024 & Prospects for Leading Companies report helps you

In summary, our 187 page report gives you the following knowledge:
• Revenues forecasts to 2024 for the overall world needle-free delivery market, 2 submarkets and 3 leading segments – discover the industry's prospects, finding promising places for investments and revenues
• Assessment of 10 leading companies, and others, discovering activities and outlooks
• Market forecasting to 2024 for 10 leading regions and countries – USA, Japan, Germany, France, UK, Spain, Italy, Rest of Europe, India, China and RoW
• View opinions from our survey, seeing 5 interviews with leading authorities
• Investigation of competition and opportunities influencing sales
• Discussion of what stimulates and restrains the needle-free delivery market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

1. Executive Summary

1.1 Sector Highlights
1.2 Aim, Scope and Format of This Report
1.3 Chapter Outline
1.4 Research and Analysis Methods
1.5 Glossary of Terms Relating to the Report

2. Introduction to Needle-Free Delivery of Drugs/Vaccines

2.1 What is Needle-Free Technology?
2.1.1 History of Needle-Free Injections (NFI)
2.2 Why the Need For Needle-Free Delivery Technology?
2.2.1 Needle Stick Injury
2.2.1.1 Blood-Borne Pathogens and Needle Stick Injury
2.2.1.2 Accidental Needle Stick Injury: A Serious Healthcare Problem
2.3 Clinical Settings Where Needle-Free Delivery Technology Will Be Beneficial
2.3.1 Pain Management
2.3.1.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.2.1 The Global Vaccine Market, 2014-2024
2.3.2.2 Needle-Free Vaccine Delivery
2.3.2.3 Mass Immunisation
2.3.3 Insulin Delivery For Diabetics
2.3.4 Paediatric Injections
2.3.5 Other Uses For Needle-Free Injection Technology
2.4 Advantages and Disadvantages of Needle-Free Injections
2.5 The Needle-Free Delivery Market
2.5.1 Jet Injectors
2.5.1.1 Concerns About Multi-use Nozzle Jet injectors (MUNJIs)
2.5.1.2 Strengths and Weaknesses of Jet Injectors
2.5.2 Competing Needle-Free Technologies
2.5.2.1 Novel Needle Technology

2.5.2.1.1 Pen Needles
2.5.2.1.2 Microneedles
2.5.2.1.3 Hollow Microneedles
2.5.2.1.4 Solid Coated Microneedles
2.5.2.1.5 Solid Biodegradable Microneedles
2.5.2.1.6 Solid Uncoated Microneedles
2.5.2.1.7 Selection of Microneedles
2.5.2.2 Inhaler Technology
2.5.2.3 Transdermal Patch Technology
2.6 Regulation of the Needle-Free Delivery Market
2.6.1 The US Regulation System
2.6.1.1 Combination Products
2.6.1.2 FDA Statement Clamps Down On Delivery of Medications in Non-approved Needle-Free Devices
2.6.2 The European Regulation System
2.6.2.1 Post Marketing Surveillance in the EU

3. The Global Needle-Free Injection Device Market, 2014-2024

3.1 The Needle-Free Delivery Technology Market: Overview
3.2 The Needle-Free Delivery Technology Market by Segments, 2012-2013
3.3 The Needle-Free Delivery Market Forecast, 2014-2024
3.4 Needle-Free Delivery Technology: Market Trends, 2014-2024

4. The Jet Injectors Technology Market, 2014-2024

4.1 The Jet Injectors Market, 2012-2013
4.2 The Jet Injectors Market Forecast, 2014-2024
4.3 Leading Devices in the Jet Injectors Market, 2014
4.3.1 Biojector 2000 (Bioject Medical Technologies)
4.3.2 SUMAVEL DosePro (Zogenix)
4.3.3 E-Jet 100 (Eurojet Medical)
4.3.4 STRATIS (Pharmajet)
4.3.5 ZetaJet (Bioject Medical Technologies)
4.3.6 LectraJet (D'Antonio Consultants International)
4.3.7 Med-Jet (Medical International Technologies)
4.3.8 Vision (Antares Pharma)
4.3.9 Glide System (Glide Pharmaceutical Technologies)
4.3.10 AdvantaJet (Activa Brand Products)
4.3.11 J-Tip (National Medical Products)
4.3.12 SQ-Pen (Diabetes Management International)
4.3.13 Vitajet3 (Bioject Medical Technologies)
4.3.14 Penjet (Penjet Corporation)
4.3.15 INJEX30 (Injex)
4.4 Jet Injectors Development Pipeline, 2014
4.4.1 Zeneo (Crossject Medical Technologies)
4.4.2 Jupiter Jet (Bioject Medical Technologies)
4.4.3 Iject (Bioject Medical Technologies)
4.4.3.1 Iject R (Bioject Medical Technologies)
4.4.4 Relday (Zogenix)
4.5 Concluding Remarks

5. Competing Needle-Free Technology Market, 2014-2024

5.1 Competing Needle-Free Technologies: Overview
5.2 Competing Needle-Free Technology Market, 2012-2013
5.3 Competing Needle Free Technologies Market Forecast by Segments, 2014-2024
5.4 Novel Needle Technology Market, 2013
5.4.1 Novel Needle Technology Market Forecast, 2014-2024
5.4.2 Leading Products in the Microneedle Technology Market, 2014
5.4.3 Microneedle Patches for Vaccine Delivery, 2014
5.4.3.1 Microneedle Patch for the Polio Vaccine (Georgia Tech's School of
Chemical and Biomolecular Engineering)
5.4.3.2 AdminPen (nanoBioSciences)
5.4.3.3 PKA SoftTouch (PKA SoftTouch Corp)
5.4.3.4 DrugMAT (TheraJect)
5.4.3.5 MicroCor (Corium International)
5.4.3.6 Nanopatch (Vaxxas)
5.4.3.7 ZP Patch Technology (Zosana)
5.5 Inhaler Technology Market, 2013

5.5.1 Inhaler Technology Market Forecast, 2014-2024
5.5.2 Inhalers in the Asthma Market, 2014
5.5.3 Inhalers in the Insulin Market, 2014
5.5.4 Inhalers in the Vaccine Market, 2014
5.6 The Patch Technology Market, 2013
5.6.1 The Patch Technology Market Forecast, 2014-2024
5.6.2 Drug Patches in the Market, 2014
5.7 Other Competing Needle-free delivery Technology in development
5.7.1 Magnetic Injection
5.7.2 Laser Injection
5.7.3 Vaccine Delivery Using Micro-Shock Waves (Indian Institute of Science, Bangalore)
5.7.4 Nanotechnology Syringes (Gwangju Institute of Science and Technology, South
Korea)
5.7.5 Nanotechnology Implant (University of California, San Francisco)

6. Leading National Needle-Free Delivery Markets, 2014-2024

6.1 Leading National Breakdown of the Needle-Free Delivery Market, 2012-2013
6.2 The Leading National Needle-Free Delivery Market Forecast, 2014-2024
6.3 The US Needle-Free Delivery Market Forecast, 2014-2024
6.4 The European Needle-Free Delivery Market, 2013
6.4.1 The European Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.1 The German Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.2 The French Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.3 The Italian Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.4 The Spanish Needle-Free Delivery Market Forecast, 2014-2024
6.4.1.5 The UK Needle-Free Delivery Market Forecast, 2014-2024
6.5 The Japanese Needle-Free Delivery Market Forecast, 2014-2024
6.6 The Chinese Needle-Free Delivery Market Forecast, 2014-2024
6.7 The Indian Needle-Free Delivery Market Forecast, 2014-2024

7. Leading Companies in the Needle-Free Delivery Market 2014

7.1 Antares Pharma
7.1.1 Sales and Performance Analysis
7.1.2 Product Sales, 2012
7.1.3 Revenue by Region, 2012
7.1.4 Revenue by Major Customers, 2011-2012
7.1.5 Sales and Performance Analysis, 3Q 2013
7.1.6 Technology of Antares Pharma
7.1.6.1 Pressure Assisted Injection Devices
7.1.6.2 Transdermal Gel System
7.1.7 Marketed Products, 2014
7.1.8 Pipeline Products, 2014
7.2 Zogenix
7.2.1 Sales and Performance Analysis
7.2.2 Sales by Segment, 2013
7.2.3 Needle-Free Products
7.2.3.1 Marketed Products, 2014

7.2.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
7.2.3.1.2 Zohydro™ ER (hydrocodone bitartrate) Extended-Release Capsules
7.2.3.1.3 Zohydro™ ER Approval: Cause for Controversy?
7.2.3.1.4 Pipeline Products, 2014
7.2.4 Collaborations
7.2.4.1 Co-promotion of Migranal Nasal Spray with Valeant
7.2.5 Manufacturing
7.3 Bioject Medical Technologies
7.3.1 Sales and Performance Analysis
7.3.2 Sales Performance Analysis by Products
7.3.3 Sales and Performance Analysis, 3Q 2012-2013
7.3.4 Bioject's Sales Revenue Setbacks
7.3.5 Collaborations
7.3.5.1 Navy Malaria Study: Utilises Bioject's B2000 Technology
7.3.5.2 Cyto Pulse Sciences: Clinical Trials for an HIV/DNA vaccine
7.3.5.3 CDA intradermal influenza study
7.3.5.4 MPI Research: Seeking Drug/Device Combinations

7.3.5.5 World Health Organisation (WHO): The Push to Eradicate Infectious Disease in Developing Countries
7.3.6 Needle-Free Products
7.3.6.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
7.3.6.2 Vitajet™: Low-cost Insulin Delivery System
7.3.6.3 ZetaJet™: Auto-disable Feature Improves User Safety
7.3.7 Needle-Free Injection Device Pipeline
7.3.7.1 Intradermal Pen Injector: Targeted Drug Delivery
7.3.7.2 Iject®: Providing Tailored Depth of Penetration
7.3.7.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
7.4 3M
7.4.1 Sales and Performance Analysis
7.4.2 3M Drug Delivery Systems
7.4.2.1 Inhalation
7.4.2.2 Transdermal patch
7.4.2.3 Microneedles
7.5 Medical International Technology (MIT)
7.5.1 Sales and Performance Analysis
7.5.2 Increased Product Awareness Through Globalisation
7.5.2.1 Further Expansion in China
7.5.3 Products
7.5.3.1 Med Jet
7.6 D'Antonio Consultants International (DCI)
7.6.1 Needle-Free Products
7.6.1.1 LectraJet®: Lightweight Device Reduces User Fatigue

7.6.2 Needle-Free Injection Device Pipeline
7.6.2.1 Low Workload Jet Injector: Single-shot Manual System
7.6.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
7.7 PharmaJet
7.7.1 Needle-Free Products
7.7.1.1 STRATIS®: Drug Delivery in Less Than a Second
7.7.1.2 Applications
7.7.2 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
7.8 Akra Dermojet
7.8.1 Needle-Free Products
7.8.1.1 DERMOJET® "HR": User-Friendly Design Allows Use in High Intensive Applications
7.8.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
7.8.1.3 Automatic DERMOJET®
7.9 Injex Pharma
7.9.1 Injex 30
7.9.1.1 Injex 30's Applications
7.9.2 Injex's Worldwide Distribution
7.9.2.1 Exclusive Distributor Agreement with Russia's Medici Ltd.
7.9.2.2 Chinese SFDA approval
7.9.2.3 NHS's Withdrawal of Injex30
7.10 Glide Pharma
7.10.1 Applications
7.10.1.1 Glide SDI system's Advantages
7.10.2 Injecting Solid Formulations
7.10.3 Pharmaceutical Companies
7.10.4 Collaboration with Pfenex Inc. To Aid Delivery of Solid Dose Vaccine

8. Qualitative Analysis of the Needle-Free Delivery Market, 2014-2024

8.1 SWOT Analysis of the Needle-Free Delivery Market, 2014-2024
8.2 Strengths
8.2.1 Strong Growth in the Biologic Drug Market
8.2.2 Increasing Development in Transdermal Delivery
8.2.3 No Specialist Training Required for Drug/Vaccine Delivery
8.2.4 Eliminating the Cold Chain Problem
8.2.5 Reduction in Needle Stick Injuries
8.3 Weaknesses
8.3.1 Healthcare Practitioners are not Familiar with Novel Delivery Systems
8.3.2 Current Inefficient Manufacturing Processes Lead to Costly Needle-Free
Technology
8.3.3 Current Technology is Very Expensive
8.4 Opportunities
8.4.1 Emerging Economies Offer Significant Growth Opportunities
8.4.2 Mass Immunisation Programs Around the World

8.4.3 Increasing Global Diabetes Population
8.4.4 Shift Towards Home Administration Setting
8.4.5 Extending Life Cycle of Drugs
8.5 Threats
8.5.1 Traditional Needles and Syringes are Very Cheap to Mass Produce
8.5.1.1 Needle and Syringes with Anti Needle-Stick Injury Technology
8.5.2 Greater Regulatory Scrutiny
8.5.3 Limited Clinical Data
8.5.4 Medical Device Excise Tax

9. Expert Opinion

9.1 Interview with Robert E. Sievers, CEO and President, Aktiv-Dry LLC, and Professor,
Department of Chemistry and Biochemistry Center for Pharmaceutical Biotechnology, University of Colorado, Boulder
9.1.1 Aktiv-Dry's PuffHaler
9.1.2 The Benefits of Inhaler Technology
9.1.3 The Competitive Landscape for Measles Inhaler Vaccines
9.1.4 ACTIV DRY'S Collaborations
9.1.5 The Challenges to Introduction Novel Inhaler Technology
9.2 Interview with David Hoey, CEO, Vaxxas
9.2.1 Vaxxas's Nanopatch™ technology
9.2.2 The Advantages of Using Nanopatch Technology in Developed and Developing
Markets

9.2.3 The Challenges of Manufacturing Patch Technology
9.2.4 The Future for the Nanopatch Technology
9.3 Professor Mark Kendall, Inventor of the Nanopatch and Co-founder of Vaxxas
9.3.1 Microneedles: Proof of Concept to Commerical Product
9.3.2 Needle Delivery Market is Still Strong
9.3.3 The Microneedle Market
9.4 Interview with John Turanin, Vice President and General Manager, Zogenix Technologies
9.4.1 The Use of Gas Power in Jet Injectors
9.4.2 The Incentives for Drug Companies in Adopting Needle-Free Delivery
9.4.3 Regulating the Needle-Free Delivery Technology Market
9.4.4 Regional Market Forecasts for Jet Injectors
9.4.5 Jet Injectors: Competitive Space and Restraints on the Market
9.4.6 Regional Market Forecasts for Jet Injectors
9.4.7 Jet Injectors: Competitive Space and Restraints on the Market
9.5 Interview with Mark Logomasini, President and CEO, Bioject Medical Technologies
9.5.1 The Spring-Powered, Gas-Powered and Battery Powered Jet Injector Markets
9.5.2 Other Competing Needle-Free Delivery Platforms
9.5.3 Regulations Determine Jet Injector Market
9.5.4 Small Needle Free Delivery Companies Requires Large External Capital

10. Conclusions

10.1 The Needle-Free Delivery Market, 2014-2024
10.2 Transdermal Delivery For Vaccine Delivery
10.3 Biologic Drugs are a Major Driver of the Needle Free Delivery Market
10.4 Strong Pipeline Will Drive the Competing Needle-Free Injection Technology Market
10.5 Concluding Remarks

List of Tables

Table 2.1 The Vaccine Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2012-2024
Table 2.2 Rationale For Needle-Free Vaccine Delivery
Table 2.3 Key Examples of Needle-Free Vaccine Delivery Systems, 2014
Table 2.4 Key Examples of Needle-Free Insulin Delivery Systems for Diabetics, 2014
Table 2.5 Advantages and Disadvantages of Needle-Free Injections
Table 2.6 Classification of Jet Injectors by Method of Propulsion

Table 2.7 Strengths and Weaknesses of Jet Injectors
Table 2.8 Pen Needle Technology by Needle Length
Table 2.9 FDA Guidance on Regulation of Needle-Free Injectors, 2014
Table 3.1 The Needle-Free Delivery Market: Revenue ($m), Market Share (%) by Segment, 2012-2013
Table 3.2 The Needle-Free Delivery Market: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 4.1 The Jet Injector Market: Revenue ($m), Market Share (%), 2012-2013
Table 4.2 The Jet Injector Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 4.3 Leading Devices in the Jet Injectors Market , 2014
Table 4.4 The Jet Injector Development Pipeline, 2014
Table 4.5 Crossject: Zeneo Development Pipeline, 2014
Table 5.1 The Competing Needle-Free Technology Market: Revenue ($m), Market Share (%) by Segment, 2012-2013
Table 5.2 The Competing Needle-Free Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%) 2012-2024
Table 5.3 The Novel Needle Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024

Table 5.4 Leading Products in the Microneedle Technology Market, 2014
Table 5.5 Leading Products in the Microneedle Technology Pipeline, 2014
Table 5.6 The Inhaler Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.7 Leading Inhalers in the Asthma Market, 2014
Table 5.8 Leading Inhalers in the Insulin Market, 2014
Table 5.9 Vaccine Inhalers Currently Under Development, 2014
Table 5.10 The Patch Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 5.11 Drug Patches in the Market, 2014
Table 6.1 The Leading National Needle-Free Delivery Markets: Revenue ($m), Market Share (%), 2012-2013
Table 6.2 The Leading National Needle-Free Delivery Market Forecasts: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.3 The US Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.4 The Leading National European Needle-Free Delivery Markets: Revenue ($m), Market Shares (%) by Country, 2012-2013
Table 6.5 The European Needle-Free Delivery Markets: Revenue ($m), CAGR (%), AGR (%) by Country, 2012-2024
Table 6.6 The German Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.7 The French Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.8 The Italian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024

Table 6.9 The Spanish Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.10 The UK Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.11 The Japanese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.12 The Chinese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 6.13 The Indian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Table 7.1 Antares Pharma: Revenue ($m), AGR (%), 2010-2012
Table 7.2 Antares Pharma: Revenue ($m), Revenue Shares (%) by Business Segment, 2012
Table 7.3 Antares Pharma: Revenue ($m), Revenue Shares (%) by Product Type, 2012
Table 7.4 Antares Pharma: Revenue ($m), Revenue Shares (%) by Region, 2012
Table 7.5 Antares Pharma: Revenue ($m) by Customer, 2011-2012
Table 7.6 Antares Pharma: Revenue ($m), Total 1Q, 2Q, 3Q, 2012-2013
Table 7.7 Antares Pharma: Products Under Development, 2014
Table 7.8 Zogenix: Revenue ($m), AGR (%), 2010-2013
Table 7.9 Zogenix: Revenue ($m), Revenue Shares (%) by Segment, 2013
Table 7.10 Bioject: Revenue ($m), Revenue Shares (%) by Product Line, 2010

Table 7.11 Bioject: Revenue ($m), Total 1Q, 2Q, 3Q 2012-2013
Table 7.12 Bioject: Summary of Technologies
Table 7.13 3M: Revenue ($bn), Revenue Shares (%) by Business Segment, 2012-2013
Table 7.14 MIT: Revenue ($m), AGR (%), 2009-2013
Table 7.15 MIT: Products, 2014
Table 7.16 Akra Dermojet: Summary of Technology
Table 7.17 Other Needle-Free Delivery Companies, 2014
Table 8.1 SWOT Analysis of the Needle-free Delivery Market, 2014-2024
Table 8.2 Average Price For Needle-Free Drug/Vaccine Delivery Technology, 2014
Table 8.3 Patent Expiries For Leading Drugs, 2014-2016
Table 10.1 The Needle-Free Delivery Market Segments: Revenue ($m), AGR (%), CAGR (%), 2013, 2018 & 2024

List of Figures

Figure 2.1 Percentage (%) of Needle-stick Injuries During the Timeline of Use to Disposal of a Device
Figure 2.2 The Vaccine Market Forecast: Revenue ($bn), AGR (%), 2012-2024
Figure 3.1 The Needle-Free Delivery Market: Revenue ($m) by Segment, 2013
Figure 3.2 The Needle-Free Delivery Market: Market Share (%) by Segment, 2013
Figure 3.3 The Total Needle-Free Delivery Market: Revenue ($m), AGR (%), 2012-2024
Figure 4.1 The Jet Injector Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.1 The Competing Needle-Free Technology Market: Revenue ($m) by Segment, 2013
Figure 5.2 The Competing Needle-Free Technology Market: Market Share (%) by Segment, 2013
Figure 5.3 The Competing Needle-Free Technology Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2012-2024
Figure 5.4 The Novel Needle Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.5 The Inhaler Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 5.6 The Patch Technology Market Forecast: Revenue ($m), AGR (%), 2012-2024

Figure 6.1 The Needle-Free Delivery Market: Revenue ($m) in Leading National Markets, 2013
Figure 6.2 The Needle-Free Delivery Market: Market Share (%) in Leading National Markets, 2013
Figure 6.3 The US Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.4 The Leading National European Needle-Free Delivery Markets: Revenue ($m) by Country, 2013
Figure 6.5 The Leading National European Needle-Free Delivery Markets: Market Share (%) by Country, 2013
Figure 6.6 The European Needle-Free Delivery Markets Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.7 The German Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.8 The French Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.9 The Italian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.10 The Spanish Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.11 The UK Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.12 The Japanese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 6.13 The Chinese Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024

Figure 6.14 The Indian Needle-Free Delivery Market Forecast: Revenue ($m), AGR (%), 2012-2024
Figure 7.1 Antares Pharma: Revenue ($m), AGR (%), 2010-2012
Figure 7.2 Antares Pharma: Revenue ($m) by Business Segment, 2012
Figure 7.3 Antares Pharma: Revenue Shares (%) by Business Segment, 2012
Figure 7.4 Antares Pharma: Revenue ($m) by Product Type, 2012
Figure 7.5 Antares Pharma: Revenue Shares (%) by Region, 2012
Figure 7.6 Antares Pharma: Revenue ($m), Total 1Q, 2Q, 3Q, 2012-2013
Figure 7.7 Zogenix: Revenue ($m), AGR (%), 2010-2013
Figure 7.8 Zogenix: Revenue Shares (%) by Segment, 2013
Figure 7.9 Bioject: Revenue ($m), 2010-2012
Figure 7.10 Bioject: Revenue ($m) by Product Line, 2010
Figure 7.11 Bioject: Revenue ($m), 1Q, 2Q, 3Q 2012-2013
Figure 7.12 3M: Revenue ($bn) by Business Segment, 2013
Figure 7.13 MIT: Revenue ($m), AGR (%), 2009-2013
Figure 8.1 The Transport Process For a Vaccine
Figure 10.1 The Total Needle-Free Delivery Market: Revenue ($m), 2013, 2018 & 2024
Figure 10.2 The Total Needle-Free Delivery Market: Revenue ($m) by Segment, 2013, 2018 & 2024

Companies Listed

3M
4P
Therapeutics
Activa Brand Products
AcuShot
Akra Dermojet
AKTIV-DRY

Alkermes
Allen & Hanburys
AllTranz
Altea Development Corporation
Altus Formulation
ALZA Pharmaceuticals
Amerisource Bergen Corporation
Anesiva
Antares Pharma
Aradigm
Astellas Pharma
AstraZeneca
B Braun
Battelle
Becton Dickinson
Berlex Laboratories
Bespak
Bioject Medical Technologies
Boehringer Ingelheim

Bristol-Myers Squibb
Cambridge Consultants
Cardinal Health Inc.
Corium International
Covidien
Crossject Medical Technology
CSL Behring
CSL Limited
CVS Pharmacy (CVS.com)
Cydex (subsidiary by Ligand)
Cyto Pulse Sciences
D'Antonio Consultants International
Daewoong Pharmaceuticals
Debiotech
Dr. Reddy's Laboratories
Durect
Echo Therapeutics
Eli Lilly
Eloquest Healthcare
EMD Serono (subsidiary MERCK KGAA)

Endo Pharmaceuticals
Eternity Healthcare
Ethical Holdings
Eurojet Medical
Evonik Industries
Felton International
Ferndale Pharma Group
Ferring
Generex
GlaxoSmithKline
Glide Pharma
Hangzhou Hema Medical equipment Co. Ltd
Injex Pharma
Intercell
IOMAI
Janssen Pharmaceuticals
JCR Pharmaceuticals
Jiangsu Hualan MIT Medical Technology (MIT China)
Johnson and Johnson
Key Pharmaceuticals

Kroger
Mallinckrodt Pharmaceuticals
MannKind
McKesson Corporation
MEDA
Medical House Products Limited
Medical International Technologies
MEDICI Ltd.
MedImmune
Merck Sorono
Mglas AG
Mystic Pharmaceuticals
nanoBioSciences
NanoPass Technologies
Napp Pharmaceuticals
National Medical Products
Nektar Therapeutics
Neumaura Pharma
Nicobrand Limited

Novartis
Novo Nordisk
Novogyne Pharmaceuticals
Nycomed
Nypro Limited
Owen Mumford
Pantec Biosolutions
Parke-Davis
Patheon UK
PenJet Corporation
Pfenex
Pfizer
Pharmacia & Upjohn
PharmaJet
Philips Medical
PKA SoftTouch Corp
PowderJect Pharmaceuticals (subsidiary of Pfizer)
PowerMed (acquired by Pfizer)
Procter and Gamble
ProStrakan

Pulse Needle-free Systems
Purdue Pharma
Sanofi
Schering
Schuco
Schwarz Pharma
Serum Institute of India
Shire
Shwarz-Pharma
Somerset Pharmaceuticals
Spruyt hillen
STAT Medical Devices
Syke Pharma
Syneron
Taizhou Amazon Investment Center
Takeda
Tapemark
Team Consulting
Teva Pharmaceutical
The Medicines Company

TheraJect
TheraTech
Trinity-Chiesi
UCB
Valeant
Valeritas
VAXXAS
Vygon
Vyteris
Watson Pharmaceuticals
Ypsomed Holiding
Zeltrix
Zogenix
Zosano Pharma
Zydus Cadil

Other Organisations Mentioned in This Report

Ankara University
Australian Institute of Bioengineering and Nanotechnology, University of Queensland
Biomedicine International
CDC Measles Eradication Committee
Center for Biologics Evaluation and Research (CBER) (US)
Center for Drug Evaluation and Research (CDER) (US)
Centers for Disease Control and Prevention (CDC)
Echo Therapeutics
Emory University
European Union (EU)
European Union Council
Gates Foundation
Georgia Tech's School of Chemical and Biomolecular Engineering
Gwangju Institute of Science and Technology
Harvard University

Indian Institute of Science
Karolinska Institutet
Leiden University Medical Centre
Massachusetts Institute of Technology (MIT)
Medical Products Agency (Sweden)
Medicine In Need (MEND)
MPI Research
National Competent Authorities (NCAs)
National Health Services (NHS)
National Institute of Health (NIH)
Population Council
Royal College of Nursing (RCN)
Seoul National University
The Accidental Blood Exposure Study Task Force (GERES) (France)
The Centre for Devices and Radiological Health (CDRH)
The China Food and Drug Administration (CFDA) (China)
The China State Food and Drug Administration (SFDA) (China)
The Food and Drug Administration (FDA) (US)
The Global Polio Eradication Initiative (GPEI)
The International Diabetes Federation (IDF)

The Ministry of Health of Oman
The Ministry of Health, Labour, and Welfare (MHLW)
The National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Health (NIH)
The Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
The Program for Appropriate Technology in Health (PATH)
The Swedish Institute for Infectious Disease Control
The University of Colorado Cooperative Institute for Research in Environmental Sciences (CIRES)
The US Army Medical Research Institute of Infectious Diseases (USAMRIID)
U.S. Navy
University Erlangen-Nurnberg
University of California
University of Colorado
University of Oxford
US Military
World Health Organisation (WHO)

To order this report: Needle-Free Delivery: Technology and Market Forecast 2014-2024
http://www.reportlinker.com/p02332847/Needle-Free-Delivery-Technology-and-Market-Forecast-2014-2024.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
All content © Copyright 2000 - 2014 WorldNow and WCAX. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.